fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

7 of 11 Sectors Close Green As Markets Settle Lower Monday – $F $PROG $QCOM $RIVN $XSPA Rise

By John F. Heerdink, Jr.
“Don’t let your ego get too close to your position, so that if your position gets shot down, your ego doesn’t go with it.” – Colin Powell, American Statesman Born: April 5, 1937


Happy Monday!

I hope that you all had a wonderful start to the week.

The markets ended with the majors drifting flat to slightly lower today as the S&P 500 closing at 4,682.60 (-.00%), the Dow 30 closing at 35,087.45 (-.04%), & the Nasdaq closing at 15,853.85 (-.04%). The small caps on the Russell 2000 also closed lower at 2,400.93 (-.45%), while the MicroCaps also dropped as the iShares Micro-Cap ETF (IWC) closed at $154.53, (-.59%). The overall down day surprisingly ended with 7 of the 11 sectors moving higher, however the more highly weighted sectors. i.e. health care, materials, & information technology were down to add the pressure.  

The U.S. Dollar Index moved up again .4% to 95.54 a level that has not been seen since the middle of 2020, the macroeconomic schedule produced the Empire State Manufacturing Survey report, which confirmed an upward move to 30.9 in November, & the yield curve widened as the 2-yr yield fell by 1 basis point to .52% & the 10-yr yield moved up by 4 four basis points to 1.62%. The precious metals markets ended with gold prices closing at $1,864, -$3/oz. and silver closed at $25.13, -$.27/oz.   

Tomorrow will bring forth the Retail Sales report for October, the Industrial Production and Capacity Utilization report, the NAHB Housing Market Index report for November, the Import and Export Prices report for October, the Business Inventories report for September, & the Net Long-Term TIC Flows report for September.

BIOTECH

The SPDR S&P Biotech ETF (XBI) closed at $123.89, -2.09%, the iShares Nasdaq Biotechnology ETF (IBB) closed at $153.18, -.53%, & the NYSE ARCA Biotech Index (^BTK) closed at $5,421.58, -.28%.

Today, Atossa Therapeutics (NASDAQ: ATOS) announced their financial results for the fiscal quarter ended September 30, 2021, and provided an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “Our progress in both the Endoxifen and COVID-19 programs, with our initiation of our trial in Australia for AT-H201, and our receipt of regulatory authorization in Sweden to commence an Endoxifen Phase 2 trial, have been key recent milestones, positioning us to move both of these programs forward and take the next steps toward developing therapies in urgent unmet patient needs. Further, our strong balance sheet will continue to facilitate our development plans as we not only execute on these trials but also explore additional options that could create significant shareholder value,” Review the balance of the story here. 

 

Shares of VP Watchlist stock INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, closed at $14.46, after reaching an intraday high of $14.88.

Last week, INMBpresented multiple poster presentations and a plenary talk at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting in Boston. Learn more. 

I recently hosted a FREE Tribe Public Presentation and Q&A event with INMB’s CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss, who delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video that has been viewed over +30.4k times now to learn more. 


CONSUMER DISCRETION – TECH – EV

Tesla (TSLA) moved lower to close at $1013.39, -1.94% as Rivian Automotive, Inc. (RIVN) jumped again to close at $149.36, +14.94% after going public last Tuesday at $78 and is now worth $131.94B.  Shares of Ford (F) closed at $19.86, +1.85%. Ford is believed to own ~12% of Rivian’s shares now worth over +$15B. On Nov. 4, Ford Motor Company and its financing subsidiary, Ford Motor Credit Company, introduced the North America auto industry’s first sustainable financing framework, focusing on and paying for ambitious plans in vehicle electrification and other environmental and social areas. On Oct, 27, Ford Motor Company (F) reported its 2021 third quarter financial results after the markets closed. Ford generated quarterly revenue of $35.7 billion, net income of $1.8 billion, adjusted EBIT of $3.0 billion; North America auto EBIT margin of 10.1%. Ford increased guidance for full-year 2021 adjusted EBIT to between $10.5 billion and $11.5 billion & expects cash flow over current planning period to be more than sufficient to fund growth priorities; announces resumption of regular stock dividend in fourth quarter.

Amazon.com, Inc. (NASDAQ: AMZN, $3,545.68, +.58%). Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company, and Qualtrics (NASDAQ: XM) announced they are expanding their relationship, with Qualtrics migrating its internal IT systems and customer-facing workloads to the world’s leading cloud. The migration includes Qualtrics’ complete portfolio of experience management (XM) applications and its xFlow automated workflow system. Qualtrics selected AWS as its preferred cloud provider to enhance operational performance, expand globally, and develop new features that help uncover deeper insights for its customers. Qualtrics will be able to provide customers with actionable insights faster and more efficiently using AWS’s proven infrastructure and broad capabilities, including machine learning, analytics, databases, security, and compute.  

Home Depot (HD), Lowe’s (LOW), Target (TGT),and Walmart (WMT) report their earnings this week. 

Shares of Apple (AAPL) closed at $168.51, +2.16%. On Nov. 10th, Apple® announced Apple Business Essentials, an all-new service that brings together device management, 24/7 Apple Support, and iCloud® storage into flexible subscription plans for small businesses with up to 500 employees. The company also unveiled a new Apple Business Essentials app that enables employees to install apps for work and request support.

Qualcomm (QCOM) closed at $164.42, +2.89% after recently beating WallStreet’s expectations last week.  View the results and their guidance here. Over the last five years, Qualcomm has reportedly invested $30M towards 160 STEM programs across the world. Similar to STEM Next, Qualcomm envisions a diverse and inclusive future STEM workforce made possible by advancing STEM education for students at all levels and from all backgrounds. During MGM’s launch last year, Qualcomm was a supportive inaugural funder and visionary leader that helped MGM create its strong–and growing–coalition of like-minded organizations.

NVIDIA (NVDA) closed $300.25, -1.2%. Last week, NVIDIA announced NVIDIA Omniverse Replicator, a powerful synthetic-data-generation engine that produces physically simulated synthetic data for training deep neural networks. In its first implementations of the engine, the company introduced two applications for generating synthetic data: one for NVIDIA DRIVE Sim™, a virtual world for hosting the digital twin of autonomous vehicles, and another for NVIDIA Isaac Sim™, a virtual world for the digital twin of manipulation robots.

Shares of Microsoft Corp. (MSFT) closed at $336.07, -.19% after last week’s release of their Q1 2022 fiscal earnings report. On November 12 Kyndryl (NYSE: KD), the world’s largest IT infrastructure services provider, and Microsoft Corp., announced a landmark global strategic partnership that will combine their market-leading capabilities in service of enterprise customers. The deal with Microsoft is Kyndryl’s first since recently becoming an independent public company and provides incremental multi-billion dollar revenue opportunities for the two companies. Together the companies will bring to market state-of-the-art solutions built on the Microsoft Cloud that will accelerate hybrid cloud adoption, modernize applications and processes, support mission-critical workloads, and further enable modern work experiences for customers.

Shares of IronNet, Inc. (IRNT), an innovative leader transforming cybersecurity through Collective Defense, closed at $10.55, +.96%. Recently, IronNet announced that it has joined the Microsoft Intelligent Security Association (MISA), a nomination-only association, demonstrating IronNet’s long-term commitment with Microsoft to deliver better security solutions to customers. As a Microsoft partner, IronNet, through its innovative Collective Defense platform, empowers Microsoft customers to execute safe and seamless migrations to the cloud amidst the increasing volume of highly-aggressive and sophisticated cyberattacks. IronNet Founder and Co-CEO, General (Ret.) Keith Alexander, “As we continue to see an increase in malicious cyberattacks against both the public and private sectors, we are pleased to join the Microsoft Intelligent Security Association to advance how we defend together. MISA’s mission directly aligns with our mission at IronNet: to develop integrated and innovative ways to better defend together against an evolving cyber threat landscape.”  On October, 29, IronNet announced that it has been named winner of the prestigious 2021 CybersecAsia Readers’ Choice Award in the Network Monitoring & Observability category. The award recognizes cybersecurity leaders in APAC for their critical roles played and advances and innovations made over the last two years.

DISNEY

Another VP Watchlist company, Walt Disney (DIS), closed $158.43, -.75%. Today, Disney launched Mickey and Friends Stay True: Stay-Cation, a nationwide campaign inspired by Mickey and Friends (otherwise known as the Sensational Six) and their passions for food, arts & fashion, and pets & play. Through six exciting and immersive city guides fans will be able to enjoy their city through a new lens. Last week,  Disney reported earnings for its fourth quarter and fiscal year ended October 2, 2021 which missed expectations. Diluted earnings per share (EPS) from continuing operations for the quarter was income of $0.09 compared to a loss of $0.39 in the prior-year quarter. Excluding certain items(1), diluted EPS for the quarter was income of $0.37 compared to a loss of $0.20 in the prior-year quarter. Diluted EPS from continuing operations for the year ended October 2, 2021 was income of $1.11 compared to a loss of $1.57 in the prior-year. Excluding certain items(1), diluted EPS for the year increased 13% to $2.29 from $2.02 in the prior-year. “This has been a very productive year for The Walt Disney Company, as we’ve made great strides in reopening our businesses while taking meaningful and innovative steps in Direct-to-Consumer and at our Parks, particularly with our popular new Disney Genie and Magic Key offerings,” said Bob Chapek, Chief Executive Officer, The Walt Disney Company. “As we celebrate the two-year anniversary of Disney+, we’re extremely pleased with the success of our streaming business, with 179 million total subscriptions across our DTC portfolio at the end of fiscal 2021 and 60% subscriber growth year-over-year for Disney+. We continue to manage our DTC business for the long-term, and are confident that our high-quality entertainment and expansion into additional markets worldwide will enable us to further grow our streaming platforms globally.”

MCD 

Shares of McDonald’s (MCD) closed at $252.94, +.91%. McDonald’s President and Chief Executive Officer, Chris Kempczinski recently recently stated, “Our third quarter results are a testament to our unparalleled scale and agility. Our global comparable sales increased 10% over 2019, which was delivered across an omnichannel experience that is focused on meeting the needs of our customers. We continue to execute our strategic growth plan and run great restaurants so that we can drive long-term, sustainable growth for all of our stakeholders.” Global comparable sales were up 12.7% in the third quarter and increased 10.2% on a 2-year basis & Year-to-date digital Systemwide sales* were about $13 billion, or over 20% of total Systemwide sales in our top six markets.

MEMES WATCH

AMC Entertainment (AMC) closed at $42.68,+6.7%.  On Nov. 12, Dreamscape, the location-based immersive virtual reality company,  announced it will open its next venue in Paramus, New Jersey, Dreamscape at AMC Garden State, at the Westfield Garden State Plaza on November 19, 2021. Launched in partnership with AMC Theatres®, Dreamscape will be located within the AMC Garden State 16 theatre. Serving the greater New Jersey and New York metro area, audiences can purchase advanced tickets for the location from dreamscapeimmersive.com. On November 8, AMC reported results for the third quarter ended September 30, 2021. AMC operated 596 domestic theatres representing essentially 100% of its domestic theatres and 351 international theatres representing approximately 99% of its international theatres. Substantially all of the Company’s theatres were open for the entirety. 

Bed Bath & Beyond Inc. (NASDAQ: BBBY) announced recently that it expects to complete its $1 billion three-year share repurchase plan by the end of fiscal 2021, two years ahead of schedule. Shares of BBBY closed at $21.58, -4.26% . 

GameStop (GME) closed at $209.14, +3.48%. On Nov. 4, GameStop announced that it has entered into a new $500 million global asset-based revolving credit facility (“ABL Facility”) with a syndicate of banks. The new five-year ABL Facility, which was oversubscribed, replaces the Company’s existing $420 million facility due in November 2022. In addition to delivering enhanced liquidity, the new ABL Facility provides for reduced borrowing costs, lighter covenants and more flexibility. Wells Fargo Bank, N.A. acted as Lead Arranger and will serve as Administrative Agent.

Shares of Seanergy Maritime Holdings Corp. (SHIP) closed at $1.01, after recently announcing its financial results for the third quarter ended September 30, 2021. Highlights of the Third Quarter of 2021: Gross revenues: $50 million in Q3 2021, as compared to $20.4 million in Q3 2020, up 146%, Net Income: $20.1 million in Q3 2021, as compared to $3.6 million in Q3 2020, up 459%, EBITDA1: $30.1 million in Q3 2021, as compared to $12.7 million in Q3 2020, up 137%, Adjusted EBITDA1: $32.2 million in Q3 2021, as compared to $7.8 million in Q3 2020, up 312%.

VP WATCHLIST HIGHLIGHTS

Our complete VP Watchlist is a list that we believe deserves consideration for short term and long term portfolio adds that include Apple, Tesla, Disney & 8 other names currently. The dedicated pages for each of these companies will enable you to stay informed and learn more about these companies daily. Please review few of the updates on a few of the VP Watchlist companies below:


  • Shares of VP Watchlist stock INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, closed at $14.46, -.41%, after reaching an intraday high of $14.88.
    • Last week, INMB presented multiple poster presentations and a plenary talk at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting held in Boston. Learn more. 
    • On Nov. 3rd, INmune Bio reported its financial results for the third quarter ended September 30, 2021 and provided a business update including the announcing of a second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) & Cash and cash equivalents of $84.5 million on September 30th. RJ Tesi, M.D., Chief Executive Officer of INmune Bio stated, “In the first patient treated in our Phase I study of INKmune™ in high-risk myelodysplastic syndrome, INKmune™ was found to safely produce cancer killing memory-like NK cells while increasing proliferation and persistence of those NK cells. As expected, the memory-like NK cells generated in vivo killed NK-resistant cancer cells in vitro. We now have data from Day 73 post first treatment and over 60% of his peripheral blood NK cells remained activated and highly functional in vitro. We are continuing to screen patients for future enrollment and are in the process of expanding the number of clinical trial sites in the UK and overseas. Our latest drug stability data allows us to extend the shelf-life to over 12 months and consequently we initiated a manufacturing scale up to secure drug supplies as the program expands. In our Phase I trial of XPro in AD, we have shown that XPro decreases biomarkers of neuroinflammation and neurodegeneration while improving biomarkers of CNS repair. We hope to demonstrate these effects on cognition in the Phase II mild AD trial that is on track to initiate later this year.” INmune Bio announced that they will deliver multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting that is being held during November 9-12 in Boston. For details please visit the following link. 
    • I hosted a FREE Tribe Public Presentation and Q&A event with INMB management today, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video now to learn more.
    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
 

  • Shares of Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, closed at $53.73/share, -3.8%. The 52-wk high is $121.16. 
    • On Nov 4, FATE reported business highlights and financial results for the third quarter ended September 30, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “The interim Phase 1 data from our FT516 and FT596 programs in relapsed / refractory lymphoma demonstrate that our off-the-shelf, iPSC-derived NK cell product candidates have the potential to deliver substantial therapeutic benefit for patients along with a differentiated safety profile that supports outpatient treatment. We look forward to sharing additional clinical data from both of these programs at the American Society of Hematology Annual Meeting in December. We also continue to be pleased with the clinical advancement of our multiplexed-engineered, iPSC-derived NK cell pipeline, where we have now successfully treated the first patients with FT516 in disease-specific expansion cohorts for lymphoma and with FT538 in combination with daratumumab for multiple myeloma. Additionally, we have successfully completed GMP manufacture and release of FT576, our multi-antigen targeted, CAR BCMA product candidate for multiple myeloma, and have initiated enrollment in our Phase 1 study.”

    • On Oct. 1, Fate announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B α3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.
    • On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.



  • Shares INVO Bioscience (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $3.30, but has legged up to $3.46 in the aftermarkets after announcing financial and operating results for the third quarter ended September 30, 2021, and providing a business update. 
  • Steve Shum CEO of INVO stated, “We continue to execute against our core mission of improving access to advanced fertility services for the many patients around the world through the use of the INVOcell solution. During the quarter, we achieved a significant milestone with the opening of our very first INVO Center, based in Birmingham, where we have commenced initial cycles. Further, we opened clinics in Atlanta, Georgia and Monterrey, Mexico to expand the INVO Center business model and we are working to open the San Francisco Bay Area clinic as soon as possible. We completed the acquisition of a Canadian-based entity that will be used to distribute the INVOcell in Canada and to develop INVO Centers in the region. With our INVO Center strategy now successfully underway, we are optimistic on the prospects for further expansion using this unique and innovative model. As part of a detailed review, we have initially identified more than 20 cities here in the U.S. that we believe have excellent characteristics in terms of demographics and level of current fertility care that would be ideal locations for an INVO Center.” READ the balance of the story here. 
    • On Nov. 8 after the market closed, INVO announced that it will regain full U.S. commercialization rights for its patented INVOcell® device due to Ferring International Center S.A.’s termination for convenience of that certain Distribution Agreement dated November 12, 2018 with INVO, which termination will officially take effect on January 31, 2022. Over the past three years, INVO has been executing on a multi-faceted commercialization strategy which includes partnering to open dedicated “INVO Centers” focused on INVOcell and the IVC procedure, and establishing agreements with distributors in key markets. The terms of the U.S. Distribution Agreement had limited the number of INVO Centers that we were allowed to operate. INVO can now further support U.S. fertility clinicians directly as the exclusive provider of INVOcell® in pursuit of our mission to bring advanced fertility care to the millions of people that are without access to treatment.
    • On October 20, INVO Bioscience, Inc. announced that four exciting poster abstracts were presented discussing INVOcell at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) being held this week in Baltimore, Maryland. “It’s extremely rewarding to see our technology highlighted at this year’s ASRM. Four independent abstracts were selected for presentation at the fertility industry’s most prominent annual meeting. On behalf of the entire INVO team, we sincerely appreciate the work of the many clinicians that now support INVOcell as a solution and thank those that contributed their independent work in advancing the understanding of the unique capabilities of INVOcell. These types of events and studies emphasize the opportunity we have to democratize advanced fertility services through the unique attributes of the INVOcell solution and bring care to the large, underserved patient population around the world,” stated Steve Shum, CEO of INVO Bioscience. LEARN MORE! 
    • On Oct. 1, INVO announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Bioscience’s management team to purchase 1,240,763 shares of its common stock at a purchase price of $3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $4.0 million. The registered direct offering is expected to close on or about October 5, 2021, subject to the satisfaction of customary closing conditions.
          • The group of investors includes members of INVO Bioscience’s management team, including Steve Shum, CEO, and Andrea Goren, CFO. Paulson Investment Company, LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent’s fees and other offering expenses. INVO Bioscience currently intends to use the net proceeds from this registered direct offering for general corporate and working capital purposes.
          • Also, on Oct. 1, INVO entered into a separate Stock Purchase Agreement with Paradigm Opportunities Fund, LP an accredited institutional investor, pursuant to which we will issue to such investor 600,703 shares of their common stock, par value $0.0001 per share for a purchase price of $3.329 per share for an aggregate purchase price of $1,999,740.29. This transaction is set to close on November 30, 2021. The Shares will be issued under the exemption from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as amended. The Purchase Agreement contains a $250,000 break-up fee whereby if either party fails to close, it will be required to pay the non-breaching party a fee of $250,000. The investor under the Purchase Agreement also agreed to a 1-year lock up period with respect to the Shares.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
    • On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, was officially opening on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”
    • Over the past 40+ years, since the first IVF baby was born, the fertility market has grown into a $20+ billion global industry. Here in the U.S., according to the most recent 2019 CDC data, approximately 330,000 IVF cycles were performed across 448 clinics, which implies a roughly $5 billion domestic marketplace. However, this represents only a small portion of the actual market as approximately 90% of infertile couples go untreated each year. There are some real challenges with bridging the gap of treating the volume of patients that need care. Patient affordability and lack of insurance coverage is often the most discussed dynamic, but that is only one part of the challenge. We believe that there is an equal or even greater challenge related to capacity limitations in the industry given the relatively small number of IVF clinics and limited human resources available which are typically only available in major metropolitan areas. We believe that INVO Biosceince’s INVOcell, without the need of expensive lab build outs, can bring much needed capacity additions and access to the market beyond the major metropolitan areas at a more affordable price.


  • Shares of VP Watchlist firm, Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $2.57, on +2.96M shares of trading volume after reaching a high of $2.75 in intraday trading. 
  • On Nov. 15, Atossa announced their financial results for the fiscal quarter ended September 30, 2021, and provided an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “Our progress in both the Endoxifen and COVID-19 programs, with our initiation of our trial in Australia for AT-H201, and our receipt of regulatory authorization in Sweden to commence an Endoxifen Phase 2 trial, have been key recent milestones, positioning us to move both of these programs forward and take the next steps toward developing therapies in urgent unmet patient needs. Further, our strong balance sheet will continue to facilitate our development plans as we not only execute on these trials but also explore additional options that could create significant shareholder value,” Review the balance of the story here. 
  •  
    • On October 21, Atossa Therapeutics, Inc. (Nasdaq: ATOS) released a short video message recognizing Breast Cancer Awareness Month, and urging women to get mammograms. In the video message, which can be found on Atossa’s website here, Dr. Quay cites that the global pandemic “changed everything” with regard to breast cancer screening, indicating that many women have ceased to seek out their mammograms since the initial COVID-19 outbreak. This is corroborated in an article in the October 2021 issue of the peer-reviewed medical journal, Preventative Medicine, which indicated this was a particular problem in women of color and those who fall in the lower income brackets.
    • On September 30, Atossa announced it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.


  • Shares of VP Watchlist stock, InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed trading at $1.39.  The 52-wk range is $1.2545 – $6.42. 
    • On November 10, InMed announced their financial results for the first quarter of fiscal year 2022 which ended September 30, 2021. “The first quarter of fiscal 2022 saw positive momentum across all of our programs,” says Eric A. Adams, InMed President & CEO. “With the completion of the BayMedica Inc. (“BayMedica”) acquisition, our integrated teams are working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol® CBC (cannabichromene) and progressing our existing programs.”
    • On October 13, InMed announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. Eric A. Adams, President and Chief Executive Officer of InMed, stated, “We are delighted to close this acquisition and welcome everyone at BayMedica to the InMed team. In the next several weeks, we will focus on corporate integration, exploring our combined manufacturing know-how and looking to accelerate revenue growth. BayMedica brings significant expertise and will help strengthen our pharmaceutical drug development efforts as well as position the Company to become a global leader in the manufacturing of rare cannabinoids.”
    • On September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”

    • I hosted the INM management team on the Tribe Public Network on Tuesday, September 21 for a 30-minute FREE Presentation and Q&A Webinar Event. Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) & Shane Johnson, MD, Co-Founder of BayMedica delievered a presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” They held a Q&A session at the end of the presentation. You may view the video of the event at the Tribe Public YouTube Channel here.
    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with a BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price target.
    • On Aug.9th, I published an informative story titled “A Recent Discussion With The CEO of InMed Pharmaceuticals (NASDAQ: INM) Regarding Development Of IntegraSyn™, A Proprietary Manufacturing Approach To Economically Produce Pharmaceutical-Grade Cannabinoids” PLEASE READ NOW.
    • On July 2nd, InMed announced that it had closed the previously announced private placement and after deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares were purchased, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. InMed intends to use the net proceeds from the offering to continue pipeline development, advance business development activities and for general working capital purposes.

Markets

Symbol Name Last Price Change % Change

Big Movers

Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Symbol Name Last Price Change % Change

Economic Reports

  • On Monday, the Empire State Manufacturing Survey report confirmed an upward move to 30.9 in November.  

Agriculture & Energy

Symbol Name Last Price Change % Change

Biotech & Healthcare

Symbol Name Last Price Change % Change

Consumer Goods & Trends

Symbol Name Last Price Change % Change

Financials & Fintech

Symbol Name Last Price Change % Change

Materials & Natural Resources

Symbol Name Last Price Change % Change

Technology & Beyond

Symbol Name Last Price Change % Change

Investing & Inspiration

  1. “Don’t let your ego get too close to your position, so that if your position gets shot down, your ego doesn’t go with it.” – Colin Powell
  2. “Good things do not come easy. The road is lined with pitfalls.” – Desi Arnaz
  3. “Honoring the sacrifices many have made for our country in the name of freedom and democracy is the very foundation of Veterans Day.” – Charles B. Rangel,
  4. “The true sign of intelligence is not knowledge but imagination.” – Albert Einstein
  5. “Trust yourself, you know more than you think you do.” – Benjamin Spock
  6. “This idea of mutual appreciation and partnerships and investment in our people is very important to me and will continue to be important.” – Dennis Muilenburg
  7. “The true secret of happiness lies in taking a genuine interest in all the details of daily life.” – William Morris
  8. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  9. “Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright
  10. “If opportunity doesn’t knock, build a door.” – Milton Berle
  11. “Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.” – Mark Twain
  12. “The smallest deed is better than the greatest intention.” – John Burroughs
  13. “It’s the steady, quiet, plodding ones who win in the lifelong race.” – Robert W. Service
  14. “When I was young I thought that money was the most important thing in life; now that I am old I know that it is.” – Oscar Wilde
  15. “A savvy entrepreneur will not always look for investment money, first.” – Daymond John
  16. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  17. “Look deep into nature, and then you will understand everything better.” -Albert Einstein

  18. “The young man knows the rules, but the old man knows the exceptions.” – Oliver Wendell Holmes, Sr.

  19. “Don’t go through life, grow through life.”– Eric Butterworth
  20. “This life is worth living, we can say, since it is what we make it.” – William James
  21. “People who think they know everything are a great annoyance to those of us who do.” –  Isaac Asimov
  22. “True life is lived when tiny changes occur.”  – Leo Tolstoy
  23. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  24. “In order to attain the impossible, one must attempt the absurd.” – Miguel de Cervantes
  25. “Aim for the moon. If you miss, you may hit a star.” – W. Clement Stone
  26. “If I had to live my life again, I’d make the same mistakes, only sooner.” – Tallulah Bankhead
  27. “The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson
  28. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  29. “Procrastination is the art of keeping up with yesterday.” – Don Marquis
  30. “Do not fear mistakes. You will know failure. Continue to reach out.” – Benjamin Franklin

  31. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden

  32. “One fails forward toward success.” – Charles Kettering

  33. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  34. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  35. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  36. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  37. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  38. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  39. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  40. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  41. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  42. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  43. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  44. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  45. “It takes a long time to grow an old friend.” – John Leonard
  46. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  47. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  48. “Man is only great when he acts from passion.” – Benjamin Disraeli
  49. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  50. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  51. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  52. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  53. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  54. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  55. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  56. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  57. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  58. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  59. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  60. “Every good painter paints what he is.” – Jackson Pollock
  61. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  62. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  63. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  64. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  65. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  66. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  67. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  68. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  69. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  70. “Eliminate emotion from your investment program.” -John C. Bogle

  71. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  72. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  73. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  74. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  75. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  76. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  77. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  78. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  79. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  80. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  81.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  82. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  83. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  84. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  85. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  86. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  87. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  88. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  89. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  90. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  91. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  92. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  93. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  94. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  95. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  96. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  97. “View health as an investment, not an expense.” – John Quelch

  98. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  99. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  100. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  101. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  102. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  103. “A problem is a chance for you to do your best.”–  Duke Ellington
  104. “The best way to predict the future is to create it.” -Peter Drucker
  105. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  106. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  107. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  108. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  109. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  110. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  111. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  112. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  113. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  114. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  115. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  116. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  117. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  118. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  119. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  120. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  121. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  122. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  123. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  124. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  125. “Modern medical advances have helped millions of people live longer, healthier lives.

  126. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  127. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  128. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  129. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  130. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  131. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  132. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  133. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  134. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  135. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  136. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  137. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  138. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  139. “Investment is most successful when it is most businesslike.” – Ben Graham

  140. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  141. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  142. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  143. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  144. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  145. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  146. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  147. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  148. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  149. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  150. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  151. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  152. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  153. “Know what you own, and know why you own it.” – Peter Lynch
  154. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  155. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  156. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  157. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  158. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  159. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  160. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  161. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  162. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  163. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  164. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  165. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  166. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  167. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  168. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  169. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  170. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  171. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  172. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  173. “No Price is too low for a bear or too high for a bull.” — Anonymous
  174. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  175. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  176. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  177. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  178. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  179. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  180. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  181. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  182. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  183. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  184. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  185. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  186. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  187. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  188. “Know what you own, and know why you own it.” – Peter Lynch
  189. “Liquidity is only there when you don’t need it.” -Old Proverb
  190. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  191. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  192. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  193. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  194. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  195. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  196. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  197. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  198. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  199. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  200. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  201. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  202. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  203. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  204. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  205. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  206. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  207. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  208. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  209. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  210. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  211. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger
Symbol Name Last Price Change % Change

Videos

Please consider viewing these interesting videos: